CSL Vifor

What CSL Vifor does

CSL Vifor is a global pharmaceutical business unit of CSL Limited (ASX: CSL), specializing in iron deficiency and nephrology therapies. Formed in August 2022 when CSL acquired Vifor Pharma for approximately $11 billion, the unit traces its heritage to 1872 in St. Gallen, Switzerland. It sells a focused portfolio including Ferinject/Injectafer (ferric carboxymaltose, approved in 87 countries), Venofer (iron sucrose, 85 countries), Maltofer (oral iron polymaltose, 76 countries), Velphoro (sucroferric oxyhydroxide, 50 countries), Mircera (long-acting erythropoiesis-stimulating agent licensed from Roche), Retacrit (epoetin alfa biosimilar licensed from Pfizer), Veltassa (patiromer), Tavneos (avacopan), Korsuva/Kapruvia (difelikefalin), Rayaldee (prolonged-release calcifediol), and Filspari (sparsentan). The nephrology portfolio is co-developed and co-commercialized through the Vifor Fresenius Medical Care Renal Pharma joint company.

The business operates two principal therapeutic segments: iron deficiency and iron deficiency anaemia (addressing heart failure, chronic kidney disease, gastroenterology, inflammatory bowel disease, patient blood management, and women's health), and nephrology (spanning all stages of kidney disease from preservation of renal function through dialysis complication management). Products are distributed through CSL Vifor's own sales organization in over 100 countries, supplemented by regional licensing and distribution partnerships (Otsuka in Canada, Kissei in Japan, CTS in the Middle East/Israel) and the Fresenius Medical Care joint venture, which supplies Mircera to over 6,500 dialysis clinics in the USA.

Revenue is generated primarily through direct pharmaceutical product sales and licensing royalties from in-licensed assets. Manufacturing is anchored at St. Gallen and Ettingen in Switzerland, with R&D laboratory operations in Schlieren. The company's go-to-market is enterprise field sales oriented toward specialists (nephrologists, hematologists, gastroenterologists) reinforced by participation in major medical congresses (ERA, ASN Kidney Week, NATA, EULAR, ESAIC) and a dedicated Science Hub for healthcare professionals. Strategic positioning rests on 150+ years of brand heritage in iron therapy, deep regulatory footprint across 50–87 countries per product, and structural access to the Fresenius dialysis channel.

Name

CSL Vifor

Legal name

CSL Limited

Website

https://viforpharma.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

CSL Vifor is a global pharmaceutical business unit of CSL Limited that develops and markets iron deficiency and nephrology therapies across 100+ countries, serving specialists and dialysis networks through proprietary products, in-licensed assets, and a joint venture with Fresenius Medical Care.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals — Iron Deficiency and Nephrology

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Iron deficiency therapy
• Nephrology pharmaceuticals
• Intravenous iron
• Kidney disease treatments
• Specialty pharma manufacturing

Headquarters

HQ city

Glattbrugg

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: CSL Vifor generates revenue through manufacturing and marketing pharmaceutical products globally in iron deficiency and nephrology therapeutic areas. Products are distributed through their own sales organization and distribution partners across over 100 countries.
2. Licensing Royalties: Revenue from licensing agreements including Mircera (licensed from F. Hoffmann-La Roche AG since 2015) and Retacrit (licensed from Pfizer, Inc., approved in USA since 2018). These arrangements provide royalty streams from partner commercialization.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

CSL Vifor develops, manufactures and markets prescription pharmaceutical products for iron deficiency and iron deficiency anaemia across heart failure, kidney disease, gastroenterology, inflammatory bowel disease, patient blood management and women's health, as well as nephrology therapies covering the full spectrum of kidney disease. The company distributes these products globally, supplemented by in-licensed assets and a joint nephrology venture with Fresenius Medical Care.

Product overview

CSL Vifor is a global pharmaceutical company specializing in iron deficiency and nephrology therapies. The company operates across two primary therapeutic areas: Iron Deficiency (including iron deficiency anaemia) with products Ferinject®, Venofer®, and Maltofer®; and Nephrology with products including Veltassa®, Rayaldee®, Tavneos®, Mircera®, Retacrit®, Velphoro®, Korsuva®, and Filspari®. The company also partners with Vifor Fresenius Medical Care Renal Pharma for nephrology solutions. With a presence in over 100 countries, CSL Vifor focuses on strategic global partnering, in-licensing, developing, manufacturing, and marketing pharmaceutical products for precision healthcare.

Differentiator

Problem solved

Functional benefit

Brands

• Ferinject: Ferric Carboxymaltose Intravenous Iron - for iron deficiency and iron deficiency anaemia
• Injectafer
• Venofer
• Maltofer
• Veltassa
• Rayaldee
• Tavneos
• Mircera
• Retacrit
• Velphoro
• Korsuva
• Kapruvia
• Filspari

Products and services

• Ferinject / Injectafer (Ferric Carboxymaltose) Intravenous iron therapy for the treatment of iron deficiency and iron deficiency anaemia across multiple therapeutic areas including heart failure, kidney disease, gastroenterology, inflammatory bowel disease, patient blood management and women's health. Marketed as Ferinject internationally and as Injectafer in the USA; approved in 87 countries.
• Venofer (Iron Sucrose) Low-dose intravenous iron therapy for the treatment of iron deficiency in patients with chronic kidney disease and other conditions. Approved in 85 countries.
• Maltofer (Oral Iron Polymaltose Complex) Oral iron therapy for the treatment of iron deficiency and iron deficiency anaemia. Approved in 76 countries.
• Veltassa (Patiromer) Potassium binder for the treatment of hyperkalemia in nephrology patients. Available in 16 countries.
• Rayaldee (Prolonged-release Calcifediol) Prolonged-release formulation of calcifediol for the management of secondary hyperparathyroidism in patients with chronic kidney disease. Launched in Germany and Switzerland.
• Tavneos (Avacopan) Oral elective inhibitor of C5aR1 for the treatment of ANCA-associated vasculitis. Approved in EU, UK, Switzerland, Australia, UAE, Kuwait, and Israel; launched in major EU markets, Australia, Japan (via Kissei) and Canada (via Otsuka).
• Mircera (Methoxypolyethylene Glycol Epoetin Beta) Long-acting erythropoiesis-stimulating agent licensed from F. Hoffmann-La Roche AG since 2015 for the treatment of anaemia associated with chronic kidney disease. Supplied to over 6,500 dialysis clinics in the USA and its territories.
• Retacrit (Epoetin Alfa-epbx) Epoetin alfa biosimilar licensed from Pfizer, Inc. and approved in the USA since 2018 for all indications of the reference drug epoetin alfa, used to treat anaemia associated with chronic kidney disease and chemotherapy.
• Velphoro (Sucroferric Oxyhydroxide) Iron-based phosphate binder for the management of hyperphosphatemia in dialysis patients. Approved in 50 countries.
• Korsuva / Kapruvia (Difelikefalin) Peripherally restricted kappa opioid receptor agonist for the treatment of pruritus in dialysis patients. Approved in US, EU, UK, Switzerland, Canada, Australia, UAE, Kuwait, Israel, and Singapore; launched in major EU markets, Germany, Austria, Sweden, France, UK, Canada, Australia, UAE, Kuwait and Israel.
• Filspari (Sparsentan) Dual endothelin-angiotensin receptor antagonist for the treatment of primary immunoglobulin A nephropathy. Approved in EU, UK, and Switzerland; launched in Germany, UK, Austria and Switzerland.

Quantifiable outcome

• Ferinject approved in 87 countries
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered core and regional.

• Pfizer, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2018Licensed Retacrit (Epoetin Alfa-epbx) from Pfizer, approved in the USA since 2018 for all indications of its reference drug, epoetin alfa.
• F. Hoffmann-La Roche AGcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2015Licensed Mircera (long-acting erythropoiesis-stimulating agent) from Roche since 2015. The product is currently supplied to over 6,500 dialysis clinics in the USA and its territories.
• Vifor Fresenius Medical Care Renal PharmacoreStrategic or Co-development PartnerJoint company partnership for nephrology products. Together with Vifor Fresenius Medical Care Renal Pharma, CSL Vifor has a strong and rapidly growing presence in nephrology, committed to launching the next generation of therapies to address the full spectrum of kidney disease.
• Kissei PharmaceuticalregionalChannel Partner/ Reseller/ DistributorKissei distributes Tavneos (Avacopan) in Japan for treatment of ANCA-associated vasculitis.
• Otsuka PharmaceuticalregionalChannel Partner/ Reseller/ DistributorOtsuka distributes Tavneos in Canada and Korsuva (Difelikefalin) in Canada.
• CTS (Corporate Technology Solutions)regionalChannel Partner/ Reseller/ DistributorCTS distributes Korsuva (Difelikefalin) in Israel as part of the Middle East partnership.
• World Federation of Hemophilia (WFH)coreStrategic or Co-development PartnerCSL has long participated in the WFH Humanitarian Aid Program to bring needed medicines to underserved parts of the world. CSL is also proud to support the WFH Path to Access to Care and Treatment (PACT) Program to advance diagnosis, enhance training and advocacy to improve national care. This aligns with CSL's commitment to improve access and equity for patients.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• GSK: Global pharma with rare disease, vaccines, and specialty therapeutics franchises overlapping with CSL Vifor's nephrology and iron deficiency focus. Comparable as a broad incumbent across specialty pharma distribution channels.
• Pfizer: Licensor of Retacrit (epoetin alfa biosimilar) to CSL Vifor and a global biopharmaceutical incumbent with significant nephrology and biosimilars portfolio. Comparable as a counterparty in CSL Vifor's licensing strategy and as a broad peer in renal anemia.
• Roche: Originator of Mircera (licensed to CSL Vifor) and a major nephrology and biologics player. Comparable as the licensor of a core CSL Vifor product and as a broader specialty pharma incumbent in nephrology.
• Amgen: Large biotech with established ESA franchise (Epogen/Aranesp) in the same nephrology anemia market CSL Vifor addresses via Mircera and Retacrit. Comparable as a specialty pharma incumbent in iron/ESA-adjacent nephrology therapeutics.
• Novartis: Major pharma with specialty and rare disease franchises, including cardiovascular and nephrology adjacencies. Comparable as a broad incumbent competing for the same specialist prescriber audience in CKD and heart failure.
• Sanofi: Global pharma with rare disease and specialty therapeutics overlap to CSL Vifor's nephrology portfolio. Comparable as a broad incumbent with product adjacencies in iron deficiency and rare renal indications; co-founding supporter of WFH humanitarian programs.

Emerging players

• Akebia Therapeutics: U.S. biopharma focused on HIF-PHI inhibitors (vadadustat) for anemia in CKD, directly competing with CSL Vifor's ESA/iron franchise. Comparable as an emerging nephrology specialist targeting the same patient population.
• Ardelyx: Developer of tenapanor and other renal/cardio-renal therapies, with overlap in nephrology patient segments addressed by Veltassa and Velphoro. Comparable as a focused emerging player in CKD complications.

Direct peers

• Vifor Fresenius Medical Care Renal Pharma: Joint venture between CSL Vifor and Fresenius Medical Care focused exclusively on nephrology products. Comparable as the closest direct peer in nephrology since it shares CSL Vifor's portfolio strategy and channel access.
• Fresenius Medical Care: World's largest dialysis services and products company and CSL Vifor's joint venture partner in Vifor Fresenius Medical Care Renal Pharma. Closely comparable given shared nephrology focus, shared commercial channel into U.S. dialysis clinics, and overlapping patient populations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/csl
• YouTubeyoutube.com/user/CSLGroup
• Facebookfacebook.com/CSLBiotechnology
• LinkedInlinkedin.com/company/csl
• Instagraminstagram.com/cslbiotechnology

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSL Vifor